Sangamo Brushes Off Phase IIb Diabetic Neuropathy Failure
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech looks to new targets -- HIV and monogenic diseases -- after a disappointing trial in diabetic neuropathy.
You may also be interested in...
Sangamo Adds To Its Own Gene Therapy Technology With Ceregene Buy
The biotech will bolster its own internal programs, as well as gain a potentially lucrative mid-stage asset through the acquisition, with no effect on its own balance sheet.
Hepatitis C, HIV, Antibiotics And Vaccines Headline Infectious Diseases Discussion At TAP Conference
In developing the infectious diseases track for this year’s Therapeutic Area Partnerships conference, planners focused on areas of unmet medical need, market potential, companies with a diversity of indications, strong science and multi-level partnering opportunities.